CMS advises ViraTherapeutics on collaboration with Boehringer Ingelheim

Munich – Biotech firm ViraTherapeutics and pharmaceutical company Boehringer Ingelheim have entered into a long-term alliance to develop a next-generation oncolytic virus platform. The deal is potentially worth up to EUR 210 million. The collaboration involves the cofinancing of ViraTherapeutics' development work by Boehringer Ingelheim. As part of the deal, Boehringer Ingelheim has the option of acquiring ViraTherapeutics after Phase I clinical development is completed.

A team from CMS Munich advised ViraTherapeutics on all legal aspects of the transaction.

Established in 2013 as a spin-out from the Medical University of Innsbruck, Austria-based ViraTherapeutics GmbH is a private biopharmaceutical company that develops innovative virus-based immunotherapeutic agents for the treatment of cancer. The firm is financed by the Boehringer Ingelheim Venture Fund (BIVF), venture capital investor EMBL Ventures and Austria Wirtschaftsservice GmbH (aws, Austria’s national promotional bank), among other investors.

Boehringer Ingelheim is one of the 20 leading pharmaceutical companies worldwide. Headquartered in Ingelheim, Germany, the company operates worldwide through 145 subsidiaries and employs a total of around 47,500 people.

CMS Hasche Sigle

Stefan-Ulrich Müller, Co-Lead Partner
Jessica Mohaupt, Associate, both Corporate
Stefan Lüft, Co-Lead Partner
Theresa Dörendahl, Associate, both IP/Life Sciences
Dr Björn Herbers, Counsel
David Wachendorfer, Associate, both Competition & EU
Roland Wutzke, Partner, Tax

Press Contact
presse@cms-hs.com